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We read with interest a recent study describing melioidosis in
the western coastal region of India.1 While the peri-equatorial
endemicity of melioidosis is well-documented in Southeast Asia
and northern Australia, descriptions in other parts of Asia expand
our understanding of its geographical reach and with this, the
management challenges.2
Singapore reported its ﬁrst case of melioidosis in 1920.3
Although most of its rural landscape has been urbanized,
melioidosis remains endemic, with 319 cases notiﬁed to the
Health Ministry between 2006 and 2011.4 Historically, no
correlation with time of year has been noted, except in 2004
when a large outbreak was linked to unprecedented rainfall.5
Fifty-six melioidosis cases were treated over 6 years at two of
the country’s largest outpatient parenteral antibiotic therapy
(OPAT) centers. Our criteria for entry into OPAT were: deferves-
cence, hemodynamic stability, and no further interventions
anticipated. Patients received continuous antibiotic infusions via
a peripherally inserted central catheter (PICC) and an elastomeric
infusor. Ceftazidime, the initial treatment of choice,6 is stable once
reconstituted.7 The daily dose was 6–8 g (100–200 mg/kg/day).8
Remarkably, 51 of 56 patients (91%) were male. Nationwide the
annual incidence for male patients is estimated to be 3–7 times
that of females.5 The median treatment duration in our series was
27 days (interquartile range (IQR) 21–32 days), of which a median
14 days (IQR 10–21 days) were spent in OPAT.
Forty-seven patients (84%) completed their planned intravenous
courses in OPAT. Of the nine who did not complete, four experienced
adverse drug reactions, two required additional surgical procedures
aimed at source control, and three deteriorated clinically due to pre-
existing co-morbidities. Most (7/9) were readmitted electively
through the OPAT service and two presented via the emergency
department, but safely, with good ultimate outcomes.
An appropriate duration of initial ‘intensive’ intravenous
antibiotic therapy is critical for the management of melioidosis,
a potentially progressive disease with a high case-fatality.9 A
subsequent eradication phase of some months utilizing oral
antibiotics is required to reduce relapse rate.8 The utilization of
OPAT in our experience is very successful and consistent with a
prior study of melioidosis in OPAT reporting completion in 59 of 73
patients (81%).10 OPAT is an important treatment option given the
necessary prolonged course of ceftazidime, which would other-
wise result in extended hospitalization.
In our series, 803 bed-days were saved. Clinicians in regions
with endemic melioidosis should consider OPAT for a safe, cost-
effective, patient-friendly treatment modality.1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
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